West VirginiaRelating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine
What it does
Plain-language analysis is being updated.
Use the official record and source text while enrichment finishes.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- Apr 11Laid over on 3rd reading 4/11/2025Latest
- Apr 11Deferred until foot of 2nd reading
- Apr 11On 3rd reading
- Apr 10Committee amendment adopted (Voice vote)
- Apr 10Read 2nd timeMinor
- Apr 10On 2nd reading
- Apr 9Read 1st timeMinor
- Apr 9Immediate consideration
- Apr 9Reported do passMinor
- Apr 8To FinanceMinor
- Apr 8Reported do pass, with amendment, but first to FinanceMinor
- Mar 27To Health and Human ResourcesMinor
- Mar 27To Health and Human Resources then FinanceMinor
- Mar 27Introduced in SenateMinor
- Mar 26Communicated to Senate
- Vote recorded PASSAGE. Result: pass.Lower
- Mar 26Passed House (Roll No. 198)Passed House
- Mar 26Read 3rd timeMinor
- Mar 26On 3rd reading, Special Calendar
- Mar 25Read 2nd timeMinor
- Mar 25On 2nd reading, Special Calendar
- Mar 24Read 1st timeMinor
- Mar 24On 1st reading, Special Calendar
- Mar 21Do pass
- Mar 18Markup Discussion
- Mar 13To House Health and Human ResourcesMinor
- Mar 13Introduced in HouseMinor
- Mar 13To Health and Human ResourcesMinor
- Mar 13Filed for introductionIntroduced